Abstract
Rhodotorula is emerging as an important cause of nosocomial and opportunistic infections. We present two cases of Rhodotorula mucilaginosa fungemia diagnosed over a period of 3 months at our hospital. The first case was of a pre-term neonate in the neonatal ICU who presented with respiratory failure and sepsis. The second involved an adult female who had been injured in a road traffic accident requiring an operation for a hematoma and was later shifted to the medical ICU. For a new hospital like ours, finding two cases of Rhodotorula fungemia within a span of 3 months prompted us to describe them in this report. These cases emphasize the emerging importance of Rhodotorula mucilaginosa as a pathogen and the importance of identification and MIC testing for all fungal isolates recovered from the blood stream.
MeSH terms
-
Amphotericin B / pharmacology
-
Amphotericin B / therapeutic use
-
Antifungal Agents / pharmacology
-
Antifungal Agents / therapeutic use*
-
Catheterization, Central Venous / adverse effects
-
Female
-
Fungemia / diagnosis*
-
Fungemia / drug therapy
-
Fungemia / microbiology
-
Humans
-
Infant
-
Infant, Newborn
-
Infant, Premature
-
Infant, Premature, Diseases / diagnosis*
-
Infant, Premature, Diseases / drug therapy
-
Infant, Premature, Diseases / microbiology
-
Microbial Sensitivity Tests
-
Middle Aged
-
Opportunistic Infections / diagnosis*
-
Opportunistic Infections / drug therapy
-
Opportunistic Infections / microbiology
-
Pyrimidines / pharmacology
-
Rhodotorula / classification
-
Rhodotorula / drug effects
-
Rhodotorula / isolation & purification*
-
Treatment Outcome
-
Triazoles / pharmacology
-
Voriconazole
-
Wounds and Injuries / therapy
Substances
-
Antifungal Agents
-
Pyrimidines
-
Triazoles
-
Amphotericin B
-
Voriconazole